PBH
Price
$50.99Alerts
Change
+$2.77 (+5.74%)
Updated
Nov 18, 12:59 PM (EDT)
Capitalization
2.04B
78 days until earnings call
Intraday BUY SELL Signals
PRGO
Price
$16.40Alerts
Change
+$0.64 (+4.06%)
Updated
Nov 18, 11:54 AM (EDT)
Capitalization
2.2B
103 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

PBH vs PRGO

PBH vs PRGO Comparison Chart in %
View a ticker or compare two or three
VS
PBH vs. PRGO commentary
Nov 18, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PBH is a Buy and PRGO is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for PBH with price predictions
Nov 17, 2026

PBH in upward trend: price rose above 50-day moving average on November 16, 2026

PBH moved above its 50-day moving average on November 16, 2026 date and that indicates a change from a downward trend to an upward trend. In 28 of 43 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 65%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 36 of 62 cases where PBH's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 58%.

The Moving Average Convergence Divergence (MACD) for PBH just turned positive on November 17, 2026. Looking at past instances where PBH's MACD turned positive, the stock continued to rise in 19 of 38 cases over the following month. The odds of a continued upward trend are 50%.

Following a +4.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where PBH advanced for three days, in 174 of 324 cases, the price rose further within the following month. The odds of a continued upward trend are 54%.

PBH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 116 of 229 cases where PBH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 51%.

Bearish Trend Analysis

The 10-day RSI Indicator for PBH moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In 16 of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at 50%.

The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PBH as a result. In 53 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 62%.

The 10-day moving average for PBH crossed bearishly below the 50-day moving average on November 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 53%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PBH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 57%.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. PBH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 62 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.062) is normal, around the industry mean (6.379). P/E Ratio (12.006) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (1.482) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (2.042) is also within normal values, averaging (183.387).

The Tickeron PE Growth Rating for this company is 71 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 74 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PBH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

A.I.Advisor
a Summary for PRGO with price predictions
Nov 17, 2026

PRGO saw its Stochastic Oscillator leaves the overbought zone

The Stochastic Oscillator for PRGO moved out of overbought territory on November 13, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 59 similar instances where the indicator exited the overbought zone. In 42 of the 59 cases the stock moved lower. This puts the odds of a downward move at 71%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for PRGO moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 22 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 71%.

The Moving Average Convergence Divergence Histogram (MACD) for PRGO turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 28 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 67%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRGO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.

PRGO broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on PRGO as a result. In 61 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 69%.

Following a +7.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where PRGO advanced for three days, in 179 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.

The Aroon Indicator entered an Uptrend today. In 121 of 204 cases where PRGO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 59%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.874) is normal, around the industry mean (6.379). P/E Ratio (-1.266) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (1.142) is also within normal values, averaging (2.202). Dividend Yield (0.073) settles around the average of (0.062) among similar stocks. P/S Ratio (0.454) is also within normal values, averaging (183.387).

The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. PRGO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 90 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRGO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

FUNDAMENTALS RATINGS
PBH vs PRGO: Fundamental Ratings
PBH
PRGO
OUTLOOK RATING
1..100
1958
VALUATION
overvalued / fair valued / undervalued
1..100
62
Fair valued
9
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
7498
PRICE GROWTH RATING
1..100
5938
P/E GROWTH RATING
1..100
7190
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PRGO's Valuation (9) in the Pharmaceuticals Other industry is somewhat better than the same rating for PBH (62). This means that PRGO’s stock grew somewhat faster than PBH’s over the last 12 months.

PRGO's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as PBH (100). This means that PRGO’s stock grew similarly to PBH’s over the last 12 months.

PBH's SMR Rating (74) in the Pharmaceuticals Other industry is in the same range as PRGO (98). This means that PBH’s stock grew similarly to PRGO’s over the last 12 months.

PRGO's Price Growth Rating (38) in the Pharmaceuticals Other industry is in the same range as PBH (59). This means that PRGO’s stock grew similarly to PBH’s over the last 12 months.

PBH's P/E Growth Rating (71) in the Pharmaceuticals Other industry is in the same range as PRGO (90). This means that PBH’s stock grew similarly to PRGO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PBHPRGO
RSI
ODDS (%)
Bearish Trend 2 days ago
50%
Bearish Trend 2 days ago
71%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
58%
Bearish Trend 2 days ago
71%
Momentum
ODDS (%)
Bearish Trend 2 days ago
62%
Bullish Trend 2 days ago
69%
MACD
ODDS (%)
Bullish Trend 2 days ago
50%
Bearish Trend 2 days ago
67%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
59%
Bearish Trend 2 days ago
65%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
57%
Bearish Trend 2 days ago
63%
Advances
ODDS (%)
Bullish Trend 2 days ago
54%
Bullish Trend 10 days ago
64%
Declines
ODDS (%)
Bearish Trend 13 days ago
57%
Bearish Trend 2 days ago
67%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
63%
Bearish Trend 2 days ago
68%
Aroon
ODDS (%)
Bullish Trend 2 days ago
51%
Bullish Trend 2 days ago
59%
COMPARISON
Comparison
Nov 18, 2026
Stock price -- (PBH: $48.22 vs. PRGO: $15.76)
Brand notoriety: PBH and PRGO are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: PBH: 95% vs. PRGO: 67%
Market capitalization -- PBH: $2.04B vs. PRGO: $2.2B
PBH [@Pharmaceuticals: Generic] is valued at $2.04B. PRGO’s [@Pharmaceuticals: Generic] market capitalization is $2.2B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $2.12K to $68.49B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.46B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PBH’s FA Score shows that 0 FA rating(s) are green while PRGO’s FA Score has 1 green FA rating(s).

  • PBH’s FA Score: 0 green, 5 red.
  • PRGO’s FA Score: 1 green, 4 red.
According to our system of comparison, PRGO is a better buy in the long-term than PBH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PBH’s TA Score shows that 6 TA indicator(s) are bullish while PRGO’s TA Score has 3 bullish TA indicator(s).

  • PBH’s TA Score: 6 bullish, 4 bearish.
  • PRGO’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, PBH is a better buy in the short-term than PRGO.

Price Growth

PBH (@Pharmaceuticals: Generic) experienced а +7.23% price change this week, while PRGO (@Pharmaceuticals: Generic) price change was -6.36% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -4.76%. For the same industry, the average monthly price growth was -7.25%, and the average quarterly price growth was -8.78%.

Reported Earning Dates

PBH is expected to report earnings on Feb 04, 2027.

PRGO is expected to report earnings on Mar 01, 2027.

Industries' Descriptions

@Pharmaceuticals: Generic (-4.76% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

View a ticker or compare two or three
Interact to see
Advertisement

PRGO and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRGO has been loosely correlated with SUPN. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if PRGO jumps, then SUPN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRGO
1D Price
Change %
PRGO100%
-2.60%
SUPN - PRGO
49%
Loosely correlated
+0.73%
ELAN - PRGO
38%
Loosely correlated
-2.12%
EVO - PRGO
35%
Loosely correlated
-5.13%
ALVO - PRGO
34%
Loosely correlated
-0.79%
PBH - PRGO
33%
Loosely correlated
+0.46%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
KEYX14.09N/A
N/A
Corgi KEYS 2x Daily ETF (KEYX)
BUFZ28.08-0.17
-0.60%
FT Vest Laddered Moderate Buffer ETF (BUFZ)
MOTI36.67-0.35
-0.94%
VanEck Morningstar International Moat ETF (MOTI)
YMAG10.07-0.10
-0.98%
YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG)
SPIT27.44-0.31
-1.12%
F/m Emerald Special Situations ETF (SPIT)